XSC
TEVA icon

X-Square Capital’s Teva Pharmaceuticals TEVA Stock Holding History

X-Square Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Sell
56,230
-15
-0% -$500 0.48% 58
2026
Q1 		$1.69M Sell
56,245
-1,536
-3% -$49.4K 0.57% 60
2025
Q4 		$1.8M Sell
57,781
-14
-0% -$345 0.59% 53
2025
Q3 		$1.17M Sell
57,795
-69
-0.1% -$1.21K 0.36% 77
2025
Q2 		$970K Sell
57,864
-1,428
-2% -$23K 0.35% 82
2025
Q1 		$911K Sell
59,292
-1,890
-3% -$33.8K 0.39% 73
2024
Q4 		$1.35M Sell
61,182
-158,981
-72% -$2.89M 0.55% 56
2024
Q3 		$3.97M Buy
220,163
+6,500
+3% +$114K 1.74% 12
2024
Q2 		$3.47M Buy
213,663
+536
+0.3% +$8.26K 1.61% 14
2024
Q1 		$3M Buy
213,127
+15,649
+8% +$197K 1.42% 19
2023
Q4 		$2.06M Sell
197,478
-5,052
-2% -$47.2K 1.14% 26
2023
Q3 		$1.52M Hold
202,530
– – 1.02% 36
2023
Q2 		$1.52M Sell
202,530
-37,110
-15% -$301K 1.02% 36
2023
Q1 		$2.12M Sell
239,640
-13,000
-5% -$129K 1.25% 21
2022
Q4 		$2.3M Sell
252,640
-1,500
-0.6% -$13.1K 1.31% 21
2022
Q3 		$2.05M Buy
254,140
+1,624
+0.6% +$14.4K 1.3% 21
2022
Q2 		$1.9M Buy
252,516
+49,165
+24% +$428K 1.14% 26
2022
Q1 		$1.91M Buy
203,351
+1,987
+1% +$16.6K 0.99% 35
2021
Q4 		$1.61M Buy
201,364
+1,006
+0.5% +$9.08K 0.81% 44
2021
Q3 		$1.95M Sell
200,358
-5,396
-3% -$50.5K 1.01% 35
2021
Q2 		$2.03M Sell
205,754
-22,217
-10% -$235K 0.96% 36
2021
Q1 		$2.63M Buy
227,971
+10,382
+5% +$119K 1.22% 17
2020
Q4 		$2.1M Buy
217,589
+12,918
+6% +$124K 1.13% 22
2020
Q3 		$1.84M Sell
204,671
-5,394
-3% -$57.1K 1.33% 18
2020
Q2 		$2.59M Buy
210,065
+2,269
+1% +$25.7K 1.84% 11
2020
Q1 		$1.87M Buy
+207,796
New +$2.13M 1.86% 15

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

X-Square Capital's TEVA Position: Q2 2026 in Review

X-Square Capital reduced its Teva Pharmaceuticals (TEVA) stake by 0.03% in Q2 2026, selling an estimated $500 and leaving 56,230 shares worth $1.91M. The position accounts for 0.48% of the portfolio, ranked #58.

X-Square Capital first reported a position in TEVA in Q1 2020 and has held it in 26 quarters since. The position peaked at $3.97M in Q3 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • X-Square Capital held 56,230 shares of Teva Pharmaceuticals worth $1.91M as of Q2 2026.
  • X-Square Capital sold 15 Teva Pharmaceuticals shares in Q2 2026, an estimated $500.
  • Teva Pharmaceuticals made up 0.48% of X-Square Capital's portfolio in Q2 2026, its #58 holding.
  • X-Square Capital first reported a position in Teva Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • X-Square Capital's Teva Pharmaceuticals position peaked at $3.97M in Q3 2024.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on X-Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.